Table 1.

Characteristics of patients in the primary and validation cohorts.

Characteristics	Primary cohort		p	Validation cohort		p
	Responder	Non-responder		Responder	Non-responder
Age, mean ± SD, years	48.75 ± 7.94	47.87 ± 8.56	0.244	46.80 ± 9.29	43.60 ± 9.72	0.264
FIGO STAGE
IB2	65 (40.63%)	13 (21.31%)	0.010*	19 (46.34%)	2 (13.33%)	0.064
IIA2	45 (28.13%)	17 (27.87%)		14 (34.15%)	7 (46.67%)
IIB-III	50 (31.25%)	31 (50.82%)		8 (19.51%)	6 (40.00%)
total	160 (72.40%)	61 (27.60%)		41 (73.21%)	15 (26.79%)
Maximum tumor diameter (cm)	5.13 ± 0.97	5.12 ± 1.35	0.111	5.10 ± 0.81	5.42 ± 0.98	0.209
CT-reported lymphatic status (%)	0.001*			0.763
LN-positive	46 (28.75%)	33 (54.10%)		20 (48.78%)	8 (53.33%)
LN-negative	114 (71.25%)	28 (45.90%)		21 (51.22%)	7 (46.67%)

Fisher Exact tests or Chi-Square were applied to compare the differences in categorical variables (CT-reported lymphatic status, pre-treatment FIGO stage). Two-sample t-test was used to compare the differences in age, pre-treatment maximum diameter of tumor. Abbreviations: LN, lymph nodes detected by CT.

^*P < 0.05.